Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 1244 results for public health guidance

  1. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  06 August 2026

  2. Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation

    In development Reference number: GID-HTG10874 Expected publication date:  20 August 2026

  3. Rehabilitation for adults with complex psychosis (NG181)

    This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.

  4. About highly specialised technologies guidance

    Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.

  5. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

  6. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    Awaiting development Reference number: GID-TA11497 Expected publication date: TBC

  7. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

  8. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  04 February 2027

  9. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  10. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

  11. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

  12. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

  13. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

  14. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC

  15. Public board meeting agenda and papers March 2025

    Agenda and papers of the NICE public board meeting on 19 March 2025